article thumbnail

DEA Approves Cocaine Derivative for Parkinson’s Research. Why Not Cannabis?

Veriheal

But recent news of the DEA’s approval of a cocaine derivative for Parkinson’s disease research has left us scratching our heads. After receiving a petition three years prior, the DEA finally answered with action, making plans to deschedule [18F]FP-CIT , a controlled substance derived from cocaine. So what gives?

DEA 98
article thumbnail

Scientists Sue DEA as it Drags its Feet and Hampers Cannabis Research

WeedAdvisor

Despite mounting evidence into cannabis’ therapeutic benefits, the DEA continues to close its eyes and plug its ears, constantly claiming that there is not enough research to support its medicinal value, according to Marijuana Moment. It could be argued that the DEA is hesitant for the sake of public safety.

DEA 111
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

DEA Gets Served Another Lawsuit for Blocking Cannabis Research

Veriheal

Nixon signed the Controlled Substance Act in 1972, placing cannabis under the category of a schedule 1 drug being highly addictive and having no medicinal value. Back in 2016, the DEA said they were starting the process of approving “additional marijuana cultivators.” ” So, what happened? Why the delay?

DEA 63
article thumbnail

The Epidiolex Effect: Will Other CBD Drugs Receive FDA and DEA Approval?

Freedom Leaf

On September 28, the DEA designated Epidiolex —a plant-based CBD pharmaceutical manufactured by the UK-based GW Pharmaceuticals—a Schedule V drug in the government’s list of controlled substances. schedules were created by the Controlled Substances Act (CSA) in 1970 and are interpreted and enforced by the DEA.

DEA 51
article thumbnail

Chacruna: Ayahuasca FOIA Requests Reveal Increased Ayahuasca Seizures, Lack of Due Process and Government Secrecy

Cannabis Law Report

Drug Enforcement Agency (“DEA”). The first concerning disclosure was that the government does not track seizures specifically under the category of “ayahuasca,” but rather, simply tracks a broad category of DMT seizures every year without differentiating between ayahuasca, smokable DMT, toad medicine, or other forms of DMT.

DEA 97
article thumbnail

A Strategy for Rescheduling Psilocybin

Canna Law Blog

To acknowledge its impressive safety record and potential for treating depression more effectively than existing therapies, the Food and Drug Administration designated psilocybin a breakthrough therapy in 2018 and 2019 for treating drug-resistant depression and major depressive disorder. Last week in Nature Medicine , I.

article thumbnail

Marijuana as Schedule III: Woe is Me?

Canna Law Blog

Many people in the cannabis industry are convinced that this HHS recommendation to the Drug Enforcement Administration (DEA) means that the DEA will undertake this rescheduling (and fairly quickly, too–which would be a huge departure from its refusal to reschedule back in 2016). Just my two cents; feel free to disagree.